NG,
MAC's transcript sets out DD's comment on this, and here's the relevant part of the reply I got:
So, look at it this way - there are an undeclared number of tests being tracked as potential billing items IF they get CMS as a payer, but for now, NO revenue is or has been recognised in the accounts.Quote:
Although we do track US tests that may be potentially claimed against CMS in the future, no provision is made in the financial accounts for these tests.
The correct stance in the circumstances, don't you agree?